The aim of this study was to investigate the level and the prognostic value of the expression of different survivin transcript variants -survivin, survivin-DEx3 and survivin-2B -in tumours of 76 soft tissue sarcoma (STS) patients. The expression of survivin transcript variants in STS tissue samples and in 12 nonmalignant control tissues was analysed by quantitative RT-PCRs. Expression levels of all survivin transcript variants were strongly elevated in STS compared to normal tissues. A positive correlation between expression of splice variants and tumour stage was found (P ¼ 0.02; v 2 test). The multivariate Cox's proportional hazards regression model revealed a 7.3-fold increased risk of tumour-related death for patients with survivin-DEx3 overexpressing tumours (P ¼ 0.007). The effect of surivivin (wildtype variant) and survivin-2B was less pronounced but still significant (2.2-and 1.9-fold, resp., Po0.05 each). Our results show for the first time that mRNA expression of survivin-variants is significantly correlated to a poor prognosis for STS patients, and we suggest expression of survivin splice variants together with tumour stage as independent predictor of survival.
The aim of this study was to investigate the level and the prognostic value of the expression of different survivin transcript variants -survivin, survivin-DEx3 and survivin-2B -in tumours of 76 soft tissue sarcoma (STS) patients. The expression of survivin transcript variants in STS tissue samples and in 12 nonmalignant control tissues was analysed by quantitative RT-PCRs. Expression levels of all survivin transcript variants were strongly elevated in STS compared to normal tissues. A positive correlation between expression of splice variants and tumour stage was found (P ¼ 0.02; v 2 test). The multivariate Cox's proportional hazards regression model revealed a 7.3-fold increased risk of tumour-related death for patients with survivin-DEx3 overexpressing tumours (P ¼ 0.007). The effect of surivivin (wildtype variant) and survivin-2B was less pronounced but still significant (2.2-and 1.9-fold, resp., Po0.05 each). Our results show for the first time that mRNA expression of survivin-variants is significantly correlated to a poor prognosis for STS patients, and we suggest expression of survivin splice variants together with tumour stage as independent predictor of survival. Keywords: soft-tissue sarcoma; survivin splice variants; prognosis Survivin, a member of the inhibitor of apoptosis family is strongly overexpressed in the vast majority of cancers (Velculescu et al., 1999; Altieri, 2003) . An association between high expression of survivin mRNA and aggressive tumour behaviour has been shown in colorectal cancer, non-small-cell lung cancer, breast cancer, gliomas and B-cell lymphoma (Altieri, 2003) . In addition to the wild-type-survivin (survivin) transcript, three transcript variants have been identified: a splice variant lacking exon 3 (survivin-DEx3), another one retaining a part of intron 2 as a cryptic exon (survivin-2B), and very recently a splice variant including novel exon 3B derived from a portion of intron 3 (survivin-3B) (Mahotka et al., 1999; Badran et al., 2004) . These splice variants are functionally different because only survivin-DEx3 has antiapoptotic properties like survivin, whereas the antiapoptotic potential of survivin-2B is markedly reduced (Mahotka et al., 1999 (Mahotka et al., , 2002b . Expression of survivin splice variants was investigated for different malignant tumours (Islam et al., 2000; Hirohashi et al., 2002; Krieg et al., 2002; Mahotka et al., 2002a; O'Driscoll et al., 2003; Yamada et al., 2003; Fangusaro et al., 2005; Ryan et al., 2005) . We could show that whole survivin mRNA expression was significantly correlated to a poor survival of soft tissue sarcoma patients (STS) (Kappler et al., 2001; Wu¨rl et al., 2002) . However, mesenchymal STS has not been investigated for expression of survivin splice variants yet. The aim of this study was to investigate if there are different expression levels of survivin transcript variants in STS and which impact these expression levels can have on STS patients' prognosis.
Results and discussion
In 12 normal tissues samples, the expression level of survivin, survivin-DEx3 and survivin-2B were on average 0.20, 0.017 and 0.047, respectively. In 76 STS samples, the average values were 3.72, 0.57 and 0.63 (which is a relationship of 6.5 : 1 : 1.1), respectively, indicating a marked increase of all splice variants. This is comparable to other different cancer cell lines where an average ratio of 5-7 : 1 : 1 was found (Li, 2003) . The calculation of the expression ratio between tumour and normal tissue with an increase of 18.6-, 33.5-, and 13.4-fold for survivin, survivin-DEx3 and survivin-2B, respectively, makes this increase even clearer. The predominant expression of the wild-type variant of survivin is in agreement with results for gastric cancer, renal cell carcinomas, leukemias, breast cancer and medulloblastomas (Krieg et al., 2002; Mahotka et al., 2002a; Nakagawa et al., 2004; Fangusaro et al., 2005; Ryan et al., 2005) .
Regarding the prognostic importance of survivin variants, we found a significant association between expression level and stage of disease (P ¼ 0.002). Remarkably, all patients with tumours of stage 3 or 4 showed an elevated expression of survivin-DEx3. As expected, 20/27 STS patients with stage 3 tumours and all patients with stage 4 tumours died of disease (Table 1) . Notably, there was also a prognostic impact of expression of survivin-DEx3 in tumour stage 2 (RR ¼ 2.9; P ¼ 0.17, univariate Cox regression model, not shown). Out of 24 stage 2 patients with an elevated expression survivin-DEx3, 13 died because of their tumour, whereas only two out of nine patients with a low expression of survivin-DEx3 succumbed to their tumour. However, the absence of stage 3 and 4 patients in the group with low expression of survivin-DEx3 did not allow an adjustment to the tumour stage in a multivariate Cox's regression model. In the multivariate Cox's proportional hazards regression model (adjusted for tumour entity, tumour localization and complete resection), an elevated expression of survivin-DEx3 was correlated to a 7.3-fold increased risk of tumour related death (P ¼ 0.007), but also the expression of survivin and survivin-2B was significantly associated with a poor survival (RR ¼ 2.2; P ¼ 0.037 and RR ¼ 1.9; P ¼ 0.047, In a multivariate Cox's proportional hazards regression model (adjusted to tumour entity, tumour localization and type of tumour resection), an elevated level of survivin-DEx3 (P ¼ 0.007; RR ¼ 7.3), survivin (P ¼ 0.037; RR ¼ 2.2) and survivin-2B (P ¼ 0.047; RR ¼ 1.9) was significantly associated with tumour-related death in STS patients Survivin-splice variant expression is a prognostic factor H Taubert et al respectively) (Table 1 and Figure 1 ). This is the first time that an association between an elevated expression of survivin splice variants and a poor outcome for STS patients is described. It is important to note that expression of survivin transcript variants is an independent prognostic marker, but it is associated with tumour stage. A possible explanation is the role of survivin during mitosis (Altieri, 2003) . The association of expression of splice variants with tumour stage may help to elucidate their relationship in STS tumorigenesis and could refine the application of tumour stage for therapy decisions.
The results of this study underscore and specifies our earlier result that detection of whole survivin mRNA is correlated to a poor prognosis of STS patients (P ¼ 0.009; RR ¼ 2.7) (Kappler et al., 2001) . However, in contrast to our finding, in gastric cancer and renal cell carcinomas, survivin 2B was decreased and survivin or survivin-DEx3 remained unchanged comparing patients with early/intermediate stages versus late stages (Krieg et al., 2002; Mahotka et al., 2002a) . Furthermore, in breast cancer, none of the survivin transcript variants could be considered as prognostic indicators of disease outcome (O'Driscoll et al., 2003) . Therefore expression of survivin transcript variants might have different impact on prognosis in various cancers.
Our previous finding that mRNA coexpression of whole survivin and hTERT results in a significantly higher risk of tumour related death for STS patients (Wu¨rl et al., 2002) can be confirmed for the mRNA coexpression of survivin or survivin-2B and hTERT (P ¼ 0.03, RR ¼ 10.3 and P ¼ 0.026, RR ¼ 4.1, respectively), but not for a coexpression of survivin-DEx3 and hTERT (P ¼ 0.079, RR ¼ 3.9) (data not shown). This finding suggests that different kinds of tumour cells may overexpress either survivin-DEx3 or survivin, and the latter cells could possess more stem cell characteristics as revealed by expression of hTERT.
In summary, expression of survivin-splice variants is significantly correlated with a poor survival for STS patients. A differentiated evaluation of survivin splice variants identifies STS patients at high-risk of tumourrelated death and could be helpful for future therapeutic applications.
Materials and methods
We examined 76 frozen primary tumour samples from 76 adult STS patients (before an adjuvant treatment) in a quantitative RT-PCR analysis (Table 1 ), all patients gave written informed consent (Institute of Pathology, University of Halle, Germany and Department of Surgery 1, University of Leipzig, Germany) (Table 1) . Furthermore, we analysed mRNA expression in nontumour tissue (muscle tissue) from 12 of the 76 patients (Table 1) .
Isolation of total RNA and cDNA synthesis were performed according to standard protocols as previously described (Kappler et al., 2001) . The cDNA was amplified by automated real-time and quantitative fluorescence PCR assays for the survivin transcript variants and GAPDH transcript using kits from Roboscreen (Roboscreen GmbH, Leipzig, Germany). Survivin transcript amounts were correlated to GAPDH transcript amounts (zeptomole [zmol, 10 À21 ] survivin mRNAs per attomole [amol, 10 À18 ] GAPDH mRNA) in duplicate measurements. An elevated expression of survivin-DEx3 was determined as an expression of >0.15 zmol survivin-DEx3/ amol GAPDH.
A multivariate regression analysis according to the Cox's proportional hazard regression model, with the overall survival as the dependent variable, was used to adjust the effect of survivin transcript variants' expression for potential independent prognostic factors. A probability (P) of o0.05 was defined as significant and the relative risk (RR) was calculated. The statistical analyses were carried out using SPSS software version 11.0 (SPSS Inc., Chicago, USA). 
